Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise In Awareness Campaigns
4.1.1.2. Research and Development
4.1.1.3. Robust Pipeline
4.1.1.4. Market Strategies
4.1.2. Restraints
4.1.2.1. No Particular Drug Targeting the Disease
4.1.2.2. Presence of Alternate Therapies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiological Analysis
5.3. Research and Developments
5.4. Pipeline Analysis
5.5. Supply Chain Analysis
5.6. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
7.1.2. Market Attractiveness Index, By Treatment Type Segment
7.2. Antipsychotic Drugs
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Non-Antipsychotic Drugs
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
8.1.2. Market Attractiveness Index, By Distribution Channels Segment
8.2. Hospital Pharmacy
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Retail Pharmacy
8.4. Online Pharmacy
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. The U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10. Competitive Landscape
10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
11. Company Profiles
11.1. Eli Lilly Company
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. H. Lundbeck A/S
11.3. Emalex Biosciences, Inc.
11.4. Teva Pharmaceutical Industries Ltd.
11.5. Therapix Biosciences Ltd.
11.6. Neurocrine Bioscience Inc.
11.7. Reviva Pharmaceuticals Inc.
11.8. Bausch Health Companies Inc.
11.9. Janssen Pharmaceuticals
11.10. Mylan N.V.
LIST NOT EXHAUSTIVE
12. DataM
12.1. Appendix
12.2. About Us and Services
12.3. Contact